Skip to main content

Table 1 Demographic and clinical characteristics at start of anti-hepatitis C virus (HCV) treatment of chronically HIV/HCV co-infected patients, 1998-2011

From: Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord

  Sustained virologic response
  Total No Yes p-value
Number of patients (%) 1309 819 (63)a 490 (37)a  
Age baseline, years 42 (38–46) 42 (38–46) 42 (37–46) 0.04
Baseline BMI     <0.0001
  < 25 329 (25b) 234 (71) 95 (29)  
  > =25 123 (9) 96 (78) 27 (22)  
 Unknown 857 (66) 489 (57) 368 (43)  
Gender     0.57
 Male 960 (73) 605 (63) 355 (37)  
 Female 349 (39) 214 (61) 135 (39)  
HIV transmission route:     0.05
 Men who have sex with men 175 (13) 91 (52) 84 (48)  
 Male, injection drug use (IDU) 595 (45) 393 (66) 202 (34)  
 Female IDU 209 (16) 127 (61) 82 (39)  
 Male heterosexual 84 (6) 55 (65) 29 (35)  
 Female heterosexual 96 (7) 62 (65) 34 (35)  
 Male other/unknown 106 (8) 66 (62) 40 (38)  
 Female other/unknown 44 (3) 25 (57) 19 (43)  
Region of origin:     0.06
 Western 1101 (84) 700 (64) 401 (36)  
 Other 116 (9) 72 (62) 44 (38)  
 Unknown 92 (7) 47 (51) 45 (49)  
CD4 at baseline (cells/μl)     
 0–349 264 (20) 163 (62) 101 (38) 0.02
 350–499 306 (23) 194 (63) 112 (37)  
  > =500 491 (38) 288 (59) 203 (41)  
 Missing 248 (19) 174 (70) 74 (30)  
Nadir CD4 (cells/ μl)     <0.001
  < 200 689 (53) 434 (63) 255 (37)  
  > =200 583 (45) 381 (65) 202 (35)  
 Missing 37 (3) 4 (11) 33 (89)  
HIV RNA levels at baseline (copies/ml)     0.99
  < =400 1082 (83) 677 (63) 405 (37)  
  > 400 227 (17) 142 (63) 85 (37)  
Hepatitis B virus co-infection     0.64
 No 1214 (93) 762 (63) 452 (37)  
 Yes 53 (4) 30 (57) 23 (43)  
 Unknown 42 (3) 27 (64) 14 (33)  
HCV RNA load at baseline     <0.0001
  < 600,000 222 (17) 99 (45) 123 (55)  
  ≥ 600,000 724 (55) 485 (67) 239 (33)  
 Missing 363 (28) 235 (65) 128 (35)  
HCV genotypes     <0.0001
 1 82 (6) 53 (65) 29 (35)  
 1a 307 (23) 234 (76) 83 (27)  
 1b 147 (11) 108 (73) 39 (27)  
 2&3 315 (24) 154 (49) 161 (51)  
 4 143 (11) 103 (72) 40 (28)  
 Other/unknown 315 (24) 177 (56) 138 (44)  
APRIc score:     <0.0001
  < 0.5 409 (31) 206 (50) 203 (50)  
 0.5–1.5 426 (32) 312 (73) 114 (27)  
  > =1.5 195 (15) 155 (79) 40 (21)  
 Unknown 279 (21) 146 (52) 133 (48)  
Decline in haemoglobin (g/dl)     0.0017
 No decline 179 (14) 126 (70) 53 (30)  
  < =2.5 227 (17) 157 (69) 70 (31)  
  > 2.5 230 (18) 127 (55) 103 (45)  
 Missing 637 (49) 409 (64) 264 (41)  
Duration of HCV treatment in weeks     <0.0001
  < =24 496 (38) 390 (79) 106 (21)  
 24-48 437 (33) 242 (55) 195 (45)  
  > 48 376 (29) 187 (50) 189 (50)  
Calendar year of start HCV treatment     <0.0001
  < =2003 266 (20) 201 (76) 65(24)  
 2003–2006 421 (32) 258 (61) 163 (39)  
  > =2006 622 (48) 360 (58) 262 (42)  
cART regimen     0.003
 PI 158 (12) 104 (66) 54 (34)  
 Boosted PI 444 (34) 296 (67) 148 (33)  
 NNRTI 284 (22) 154 (54) 130 (46)  
 PI + NNRTI 50 (6) 35 (70) 15 (30)  
 No PI and/or NNRTI 131 (10) 90 (69) 41 (31)  
 no cART 242 (18) 140 (58) 102 (42)  
Backbone     <0.0001
 Start after HCV treatment 242 (18) 140 (58) 102 (42)  
 ABC + 3TC 189 (14) 117 (62) 72 (38)  
 AZT + 3TC 140 (11) 99 (62) 41 (29)  
 FTC + TDF 262 (20) 147 (56) 115 (44)  
 TDF + 3TC 130 (10) 68 (52) 62 (48)  
 TDF + ABC 44 (3) 27 (61) 17 (39)  
 d4T + 3TC 90 (7) 68 (76) 22 (24)  
 other 212 (16) 153 (72) 59 (28)  
  1. apercentage in these colums are representing the percentage of the total number of patients in a specific category/row
  2. bPercentage from total number of patients included in this study (n = 1309)
  3. cAPRI, aspartate amino transferase-to-platelet ratio; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase; NRTI, nucleoside analog reverse-transcriptaseinhibitor; ABC, abacavir, 3TC, lamivudine; AZT, zidovudine; FTC, emtricitabine; TDF, tenofovir; d4T, stavudine